Abstract
Background
Scrub typhus is an acute infectious disease caused by Orientia tsutsugamushi. Guillain–Barre syndrome (GBS) is an autoimmune-mediated peripheral neuropathy with a frequent history of prodromal infections, but GBS associated with scrub typhus is very rare.
Case presentation
We report a 51-year-old male patient who developed dysarthria and peripheral facial paralysis following the cure of scfrub typhus. CSF examination and electrophysiological findings suggested a diagnosis of GBS. After treatment with intravenous immunoglobulin, the patient’s neurological condition improved rapidly.
Conclusions
Scrub typhus infection is likely to be a potential predisposing factor in GBS, while scrub typhus-associated GBS has a favorable prognosis.
Keywords: Guillain–Barré syndrome, Anti-sulfatide antibodies, Scrub typhus, Case report, Neuropathy
Background
The etiological agent of scrub typhus is Orientia tsutsugamushi, which is characterized clinically by fever, eschar, splenomegaly, hepatomegaly, pneumonia, meningitis, and even multiple organ dysfunction [1]. Guillain–Barre syndrome (GBS) is an immune-mediated acute polyradiculoneuropathy associated with prodromal infections, injectable vaccines, malignancies, etc [2]. GBS has prodromal symptoms of infection that are mostly respiratory and gastrointestinal and is very rare in association with scrub typhus. To our knowledge, this is the first case of a GBS patient with elevated anti-sulfatide antibodies associated with scrub typhus infection.
Case presentation
The patient was a 51-year-old male who was hospitalized due to fever for 10 days. The highest body temperature was approximately 39.0 ℃, and the fever had no obvious regularity, accompanied by head pain when fever was present. On examination, it was noted that there was an eschar over the right inguinal area, and several yellow bean-sized lymph nodes were palpable over the right inguinal area, with mild tenderness. Routine blood tests suggested a white blood cell count of 12.52 *109/L, with 0% eosinophils. Meanwhile, metagenomic next-generation sequencing (mNGS) technology was used to detect pathogenic microbial DNA in blood, and as a result, 11,260 Orientia tsutsugamushi-specific sequences were detected. The patient was given intravenous treatment with doxycycline, and the patient was discharged after the resolution of symptoms of infection and continued oral doxycycline treatment as directed after discharge.
On the third day after discharge, also on the 15th day of presentation with febrile symptoms, the patient developed dysarthria, accompanied by salivation, weakness with closed eyes, and no limb weakness or numbness. Examination revealed that the patient had bilateral peripheral facial palsy, unclear articulation, dysphagia, pharyngeal reflexes were present, tendon reflexes of both lower limbs were reduced, and muscle strength of the four limbs was normal. The patient’s vital signs were uneventful, afebrile, conscious, bilateral pupils of consistent size, sensitive to light reflexes, and negative for signs of meningeal stimulation. Sensory and cerebellar examination was normal. CSF protein quantification was 2.04 g/L, white blood cell count was 6 *106/L, CSF pressure, sugar and chloride were within normal ranges, and no pathogenic sequences were detected by mNGS of CSF. Serum anti-sulfatide IgM and IgG antibodies (western blot) were positive. CSF anti-sulfatide antibody IgG (western blot) was positive. Nerve conduction studies showed slowing of NCV in the peripheral nerves of all four limbs, mild prolongation of motor nerve conduction latencies, low distal SNAP amplitude, and marked prolongation of the F-wave latency in both median and tibial nerves in electrophysiological findings, suggesting demyelination. The patient was given intravenous administration of immunoglobulin (IVIG) therapy (0.4 g/kg/day) for 5 days, and after treatment, the patient’s neurological deficit improved significantly, and no significant sequelae were left at the follow-up visits.
Discussion and conclusions
The patient presented with clinical manifestations of cranial neuropathy and albuminocytological dissociation in CSF with elevated anti-sulfatide antibodies in serum and CSF, which may be considered atypical GBS. Although the typical clinical picture of GBS syndrome with limb weakness and numbness was not present, decreased tendon reflexes in the lower extremities and peripheral neuropathy of the extremities suggested by electromyography were present.
Anti-sulfatide antibodies are associated with autoimmune neuropathy diseases and may play a role in demyelinating pathogenesis [3]. Elevated anti-sulfatide antibodies have been reported in cases of GBS [4]. Most of the patients with anti-sulfide antibody positivity had sensory or sensorimotor neuropathy in the distal extremities, and only a few of them had demyelinating neuropathy [5]. Although this patient with positive anti-sulfide antibodies had cranial nerve damage as the primary clinical manifestation, a nerve conduction study was suggestive of the presence of a demyelinating peripheral neuropathy involving motor and sensory nerves in the extremities. In fact, patients with anti-sulfatide IgM antibody positivity often present different neurophysiological and pathological findings and therapeutic responses in the peripheral nervous system [6].
Scrub typhus, a febrile disease caused by the gram-negative coccal bacterium Orientia tsutsugamushi, is transmitted to humans through the bites of infected larval mites and is commonly characterized clinically by fever, eschar, rash, splenomegaly, hepatomegaly, and lymphadenopathy and, in severe cases, meningoencephalitis, multiorgan dysfunction, and disseminated intravascular coagulation [1, 7]. Scrub typhus infection can usually involve the central nervous system, and approximately one-fifth to three-thirds of patients with scrub typhus suffer from neurological complications, but the appearance of symptoms of peripheral neuropathy is very rare [8–10]. A summary of sixteen case reports of GBS associated with scrub typhus, including the present case, is provided in Table 1 [11–20]. Among all the cases with available details of medical history, all patients developed GBS-related symptoms at least 7 days after presenting symptoms of scrub typhus infection and most concentrated at 10 to 17 days, with a mean of 10.6 days. The mean age of the reported patients was 46 years (7–74 years), and most of them were men (12 men out of 16 cases: 75%). Symptoms of these scrub typhus-associated cases of GBS include muscle weakness, cranial nerve palsy, hypotonia, decreased or absent tendon reflexes, sensory disturbances, abducens nerve palsy, and in severe cases, respiratory failure and disturbance of consciousness. For patients with GBS and persistent scrub typhus infection, fever and meningeal irritation signs may be positive. Albuminocytological dissociation (by the Brighton criteria [21]) was present in 14 of these 16 patients with CSF results and in 2 with CSF results within the normal range, although it is not clear on the basis of the current data that these CSFs were sampled in the weeks after the onset of peripheral neurological symptoms.
Table 1.
Summary of case reports of Guillain Barre syndrome associated with scrub typhus
Case Author (year) | Age (yrs)/Sex | Onseta (day-weeks) | Neuropathic symptoms | Findings | Nerve conduction study | Treatments | Outcomes |
---|---|---|---|---|---|---|---|
1 Lee et al. [11] (2007) | 42/F | 2 weeks | quadriparesis, facial diplegia, areflexia | albuminocytological dissociation in CSFb | demyelinating neuropathyc | IVIg | improvement |
2 Lee et al. [12] (2009) | 54/m | 17 days | facial paralysis, quadriparesis, hyporeflexia. | CSF normal |
prolonged F-responses, slowed NCV |
doxycycline, prednisolone, IVIg | improvement |
3 Lee et al. [12] (2009) | 74/F | 10 days | quadriparesis, hyporeflexia. | CSF normal. |
prolonged distal latencies, slowed NCV and reduced amplitude of CMAP |
antibiotics, prednisolone, IVIg | improvement |
4 Ju et al. [13] (2011) | 46/F | 7 days | quadriparesis, disturbance of consciousness, respiratory failure, hyporeflexia | albuminocytological dissociation in CSFb | acute sensoriomotor polyneuropathyc |
antibiotics, mechanical ventilation, rehabilitation therapy |
improvement |
5 Ju et al. [13] (2011) | 60/m | 8 days |
quadriparesis, disturbance of consciousness, dysphagia, sensory disturbance, respiratory failure, hyporeflexia |
GM1 IgM and GD1b IgM antibodies positive, albuminocytological dissociation in CSFb |
diffuse demyelinated neuropathyc |
IVIg, doxycycline, mechanical ventilation | improvement |
6 Sawale et al. [14] (2014) | 41/m | 15 days |
quadriparesis, facial paresis, hypotonia, the anterior abdominal muscles and paraspinal muscles weakness; deep tendon areflexia |
albuminocytological dissociation in CSFb |
absent F-waves, prolonged latency, slowed NCV and reduced amplitude of CMAP |
plasmapheresis | improvement |
7 Kim et al. [15] (2014) | 70/m | 2 weeks | ophthalmoplegia with bilateral ptosis, facial diplegia, gait ataxia, areflexia | albuminocytological dissociation in CSFb | reduced SNAP and absent H-reflexes | IVIg | improvement |
8 Sakai et al. [19] (2016) | 66/m | 7 days |
quadriparesis, dysphagia, sensory disturbance, hyporeflexia |
albuminocytological dissociation in CSFb, IgM-GD1a、IgM-GT1b、IgM-GalNAc-GD1a Positive | prolonged distal latencies, sensory potential not drawn out | IVIg | improvement |
9 Sakai et al. [19] (2016) | 58/F | 15 days | quadriparesis, facial diplegia, sensory disturbance, hyporeflexia, respiratory failure | albuminocytological dissociation in CSFb | prolonged distal latencies, reduced amplitude of CMAP, sensory potential not drawn out | IVIg, mechanical ventilation | improvement |
10 Gangula et al. [16] (2017) | 40/m | 10 days |
hypotonia, areflexia quadriparesis |
plasmodium falciparum coinfection; albuminocytological dissociation in CSFb |
reduced amplitude of SNAP、 CMAP, absent F-waves, prolonged distal latency, slowed NCV |
antimalarials, antibiotics, physiotherapy | improvement |
11 Dev et al. [17] (2019 | 20/m | 8 days | quadriparesis, hypotonia, deep tendon areflexia |
leptospirosis coinfection, albuminocytological dissociation in CSFb |
acute inflammatory demyelinating polyradiculo-neuropathyc |
antibiotics, supportive measures | improvement |
12 Juneja et al. [18] (2020) | 42/m | 7 days |
quadriparesis, hypotonia, trunk and neck muscles weakness, deep tendon areflexia |
albuminocytological dissociation in CSFb |
prolonged distal latencies, reduced NCV, and absent F responses |
IVIg | improvement |
13 Pandey et al. [20] (2021) | 56/m | 1 week |
quadriparesis, facial diplegia, abducens nerve palsy, areflexia |
albuminocytological dissociation in CSFb |
demyelinating patterns of motor neuropathiesc |
doxycycline, IVIg, supportive measures | improvement |
14 Raghunathan et al. [24](2022) | 7/m | 1 week | quadriparesis, areflexia, truncal weakness disturbance of consciousness, neck stiffness | albuminocytological dissociation in CSFb |
absent H-reflexes, absent F responses |
IVIg, azithromycin | improvement |
15 Modi et al. [25] (2023) | 20/m | 10 days | fever, disturbance of consciousness, quadriparesis, deep tendon areflexia, respiratory failure | albuminocytological dissociation in CSFb. | reduced amplitude of CMAP | doxycycline, IVIg, mechanical ventilation, rehabilitation therapy | improvement |
16 The present case | 51/m | 15 days | facial diplegia, unclear articulation, dysphagia, hyporeflexia | albuminocytological dissociation in CSFb. anti-sulfatide antibodies positive. | slowed NCV, prolonged CMAP, reduced amplitude of SNAP, prolonged F- waves | IVIg | improvement |
a Temporal onset of time from fever or other symptoms associated with scrub typhus to the appearance of symptoms of peripheral nerve impairment
b Albuminocytological dissociation in CSF: elevation of cerebrospinal protein above the laboratory normal AND total CSF white cell count <50 cells/µl according to the Brighton criteria [21]
c No detailed examination results available
Abbreviations: intravenous immunoglobulin: IVIg; SNAP: sensory nerve action potential; CMAP: compound muscle action potential; NCV: nerve conduction velocity
From Table 1, 10 patients developed GBS-related symptoms at the same time as scrub typhus infection, and the remaining 6 patients developed symptoms after the cure of scrub typhus. Among all the cases with available treatment details, 10 patients had concomitant scrub typhus infection, 3 used antibiotics, 2 used antibiotics, IVIg and prednisolone, 4 used antibiotics and IVIg, and 1 used IVIg (unclear whether antibiotics were used). Of the 6 patients with GBS following scrub typhus infection, 5 received IVIg, and 1 received plasmapheresis. Four patients used mechanical ventilation because of respiratory failure due to respiratory muscle weakness. This suggests that antibiotic therapy is essential in cases of GBS with persistent scrub typhus infection, that the addition of prednisolone and immunoglobulin may be considered when treatment is suboptimal and that treatment with immunoglobulins or plasmapheresis can be routinely administered in cases of GBS following scrub typhus infection. All the reviewed patients experienced near complete improvement of their peripheral nerve symptoms, and none died or had sequelae affecting daily tasks, implying a better prognosis for scrub typhus-associated GBS.
Numerous infectious agents have been associated with the onset of GBS and consequently with the production of antiganglioside antibodies [22]. Antiganglioside antibodies are detected in more than half of GBS patients, and their detection strongly supports the diagnosis of GBS [23]. Although antiganglioside antibodies assist in GBS diagnosis, their signal is not strong in GBS caused by scrub typhus infection. Only two patients out of 7 cases in which ganglioside-related antibody testing was performed were positive [11, 13, 15, 19, 20]. Furthermore, only GM1, GD1a, GD1b, GT1b, GalNAc-GD1a and anti-sulfatide antibodies were detected in the current reviewed cases of GBS associated with scrub typhus infection. The underlying mechanism may be an immune-mediated type 2 hypersensitivity reaction against self-antigens [10].
In conclusion, scrub typhus infection is likely to be a potential predisposing factor in GBS, although the immunological mechanisms involved are not clear. The possibility of GBS should be considered in patients who present with symptoms of peripheral neuropathy at the time of scrub typhus infection or after a recent cure. Meanwhile, assessment of whether scrub typhus infection is still present may be necessary. The timely use of antibiotics to treat scrub typhus may improve the symptoms of GBS. For GBS after the cure of tsutsugamushi disease, treatment means such as IVIg or plasmapheresis receive relatively good results. Finally, combined with the current literature that has been reviewed, scrub typhus-associated GBS has a favorable prognosis.
Acknowledgements
Not applicable.
Author contributions
Shijun Hu and Zhichuan lin carried out the data collection, literature review and drafting of the manuscript. Tao Liu and Shixiong Huang contributed to the drafting of the manuscript and aided in the literature review. Hui Liang help to draft the manuscript and revised the final version of the manuscript. All authors read and approved the final manuscript.
Funding
This study was supported by Hainan Province Clinical Medical Center, Natural Science Foundation of Hainan Province (Ref No.: 823QN343; 821RC675), Hainan Academician Innovation Platform Scientific Research Project (YSPTZX202135) and The innovation platform for Academicians of Hainan Province.
Data availability
Not applicable.
Declarations
Ethics approval and consent to participate
The patient was treated in accordance with the Declaration of Helsinki. The patient provided informed consent for all procedures. Informed consent was obtained from the patient for inclusion in this study.
Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images.
Disclosure
The authors report no disclosures relevant to the manuscript.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Shijun Hu and Zhichuan lin have contributed equally to this work and share first authorship.
References
- 1.Musa TH, Ahmad T, Wana MN, Li W, Musa HH, Sharun K, et al. The epidemiology, diagnosis and management of scrub typhus disease in China. Hum Vaccines Immunother. 2021;17:3795–805. doi: 10.1080/21645515.2021.1934355. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Papri N, Islam Z, Leonhard SE, Mohammad QD, Endtz HP, Jacobs BC. Guillain-Barre syndrome in low-income and middle-income countries: challenges and prospects. Nat Rev Neurol. 2021;17:285–96. doi: 10.1038/s41582-021-00467-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Meehan GR, McGonigal R, Cunningham ME, Wang Y, Barrie JA, Halstead SK, et al. Differential binding patterns of anti-sulfatide antibodies to glial membranes. J Neuroimmunol. 2018;323:28–35. doi: 10.1016/j.jneuroim.2018.07.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Rinaldi S, Brennan KM, Kalna G, Walgaard C, van Doorn P, Jacobs BC, et al. Antibodies to heteromeric glycolipid complexes in Guillain-Barre syndrome. PLoS ONE. 2013;8:e82337. doi: 10.1371/journal.pone.0082337. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Dabby R, Weimer LH, Hays AP, Olarte M, Latov N. Antisulfatide antibodies in neuropathy: clinical and electrophysiologic correlates. Neurology. 2000;54:1448–52. doi: 10.1212/WNL.54.7.1448. [DOI] [PubMed] [Google Scholar]
- 6.Campagnolo M, Ferrari S, Dalla Torre C, Cabrini I, Cacciavillani M, Lucchetta M, et al. Polyneuropathy with anti-sulfatide and anti-MAG antibodies: clinical, neurophysiological, pathological features and response to treatment. J Neuroimmunol. 2015;281:1–4. doi: 10.1016/j.jneuroim.2015.02.009. [DOI] [PubMed] [Google Scholar]
- 7.Lv Y, Guo XG, Jin DC. Research progress on Leptotrombidium deliense. Korean J Parasitol. 2018;56:313–24. doi: 10.3347/kjp.2018.56.4.313. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Rana A, Mahajan SK, Sharma A, Sharma S, Verma BS, Sharma A. Neurological manifestations of scrub typhus in adults. Trop Doct. 2017;47:22–5. doi: 10.1177/0049475516636543. [DOI] [PubMed] [Google Scholar]
- 9.Misra UK, Kalita J, Mani VE. Neurological manifestations of scrub typhus. J Neurol Neurosurg Psychiatry. 2014;86:761–6. doi: 10.1136/jnnp-2014-308722. [DOI] [PubMed] [Google Scholar]
- 10.Garg D, Manesh A. Neurological facets of scrub typhus: a comprehensive narrative review. Ann Indian Acad Neurol. 2021;24:849–64. doi: 10.4103/aian.aian_739_21. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Lee SH, Jung SI, Park KH, Choi SM, Park MS, Kim BC, et al. Guillain-Barre syndrome associated with scrub typhus. Scand J Infect Dis. 2007;39:826–8. doi: 10.1080/00365540701266755. [DOI] [PubMed] [Google Scholar]
- 12.Lee MS, Lee JH, Lee HS, Chang H, Kim YS, Cho KH, et al. Scrub typhus as a possible aetiology of Guillain-Barre syndrome: two cases. Ir J Med Sci. 2009;178:347–50. doi: 10.1007/s11845-008-0226-z. [DOI] [PubMed] [Google Scholar]
- 13.Ju IN, Lee JW, Cho SY, Ryu SJ, Kim YJ, Kim SI, et al. Two cases of scrub typhus presenting with Guillain-Barre syndrome with respiratory failure. Korean J Intern Med. 2011;26:474–6. doi: 10.3904/kjim.2011.26.4.474. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Sawale VM, Upreti S, Singh TS, Singh NB, Singh TB. A rare case of Guillain-Barre syndrome following scrub typhus. Neurol India. 2014;62:82–3. doi: 10.4103/0028-3886.128340. [DOI] [PubMed] [Google Scholar]
- 15.Kim KW, Kim YH, Kim BH, Lee CY, Oh MS, Yu KH, et al. Miller Fisher syndrome related to orientia tsutsugamushi infection. J Clin Neurosci. 2014;21:2251–2. doi: 10.1016/j.jocn.2014.04.014. [DOI] [PubMed] [Google Scholar]
- 16.Gangula RS, Stanley W, Vandanapu A, Prabhu MM. Guillain-Barre syndrome with falciparum malaria and scrub typhus mixed infection-an unusual combination. J Clin Diagn Res. 2017;11:OD10–1. doi: 10.7860/JCDR/2017/28390.10629. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Dev N, Kumar R, Kumar D. Guillain–Barre syndrome: a rare complication of leptospirosis and scrub typhus co-infection. Trop Doct. 2019;49:248–9. doi: 10.1177/0049475519836038. [DOI] [PubMed] [Google Scholar]
- 18.Juneja A, Anand K, Shah M. Guillain–Barre syndrome: a rare occurrence following scrub typhus. Niger J Med. 2020;29:337–8. doi: 10.4103/NJM.NJM_36_20. [DOI] [Google Scholar]
- 19.Sakai K, Ishii N, Ebihara Y, Mochizuki H, Shiomi K, Nakazato M. Guillan-Barre syndrome following scrub typus: two case reports. Rinsho Shinkeigaku. 2016;56:577–9. doi: 10.5692/clinicalneurol.cn-000864. [DOI] [PubMed] [Google Scholar]
- 20.Pandey S, Chaudhari D, Renjen PN, Ahmad K. Guillain-Barre’ syndrome following scrub typhus: a rare case. Ann Indian Acad Neurol. 2021;24:451–2. doi: 10.4103/aian.AIAN_471_20. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R, et al. Guillain-Barre syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011;29:599–612. doi: 10.1016/j.vaccine.2010.06.003. [DOI] [PubMed] [Google Scholar]
- 22.Cutillo G, Saariaho AH, Meri S. Physiology of gangliosides and the role of antiganglioside antibodies in human diseases. Cell Mol Immunol. 2020;17:313–22. doi: 10.1038/s41423-020-0388-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Koga M, Takahashi M, Yokoyama K, Kanda T. Ambiguous value of anti-ganglioside IgM autoantibodies in Guillain-Barre syndrome and its variants. J Neurol. 2015;262:1954–60. doi: 10.1007/s00415-015-7806-4. [DOI] [PubMed] [Google Scholar]
- 24.Raghunathan V, Dhaliwal M, Singhi P, Singhi S. Scrub typhus associated with guillain-barre syndrome (GBS) Indian J Pediatr. 2022;89:1129–30. doi: 10.1007/s12098-022-04312-y. [DOI] [PubMed] [Google Scholar]
- 25.Modi T, Sood T, Moudgil S, Arora NAO. Neurological manifestations of scrub typhus: encephalitis and Guillain-Barré syndrome (GBS) BMJ Case Rep. 2023;16:e253350. doi: 10.1136/bcr-2022-253350. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Not applicable.